Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.70
+0.11 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV
May 13, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
May 11, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
May 06, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Product Recall
Exposures
Legal
Product Safety
Opinion: The Road to Ending Visceral Leishmaniasis
May 03, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
May 02, 2022
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027 Bio-based Platform Chemicals Market Overview The Bio-based Platform Chemicals Market size is forecast to reach...
Via
iCrowdNewswire
Topics
Derivatives
Exposures
COVID-19
Derivatives
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
May 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
On Earth Day, Gilead Marks Strides in Environmental Sustainability
April 29, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Emissions
Gilead Sciences Announces First Quarter 2022 Financial Results
April 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
April 26, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
April 26, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
April 25, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
April 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
April 20, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
April 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
The Translatinx Network Helps a Resilient Community 'Live Its Truth'
April 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum
April 15, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
April 14, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Four Questions With Anu Osinusi: Gilead's Commitment to People Living With Viral Hepatitis
April 13, 2022
SOURCE: Gilead Sciences
Via
3BL Media
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
April 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
April 11, 2022
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
At the Forefront of HIV Health and Healing in Spain: Ferran's Story
April 06, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
April 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Hope for Haiti Kicks Off Fourth Annual Hike for Haiti Challenge Campaign to Provide Access to Education and Public Health
April 01, 2022
Feel-good global movement supported by high-profile ambassadors and brands helping to fund organization's $12M plan for school rebuilding and rehabilitation following the devastating 7.2 magnitude...
Via
Newswire.com
Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story
April 01, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Claflin University's Deeply Rooted Commitment to Social Justice
March 30, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
March 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey
March 25, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Opinion: Searching for the Next Generation of Sustainable Health Care
March 22, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO
March 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.